S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

E. Matutes, Immunophenotyping and differential diagnosis of hairy cell leukemia, Hematol Oncol Clin North Am, vol.20, issue.5, pp.1051-1063, 2006.

J. J. Waterfall, E. Arons, and R. L. Walker, High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairycell leukemias, Nat Genet, vol.46, issue.1, pp.8-10, 2014.

T. Robak, E. Matutes, D. Catovsky, P. L. Zinzani, and C. Buske, Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.26, issue.5, pp.100-107, 2015.

X. Troussard and E. Cornet, Proliférations lymphoïdes B matures à cellules chevelues, Ann Biol Clin, vol.73, issue.4, pp.399-406, 2015.

E. Maitre, P. Bertrand, and C. Maingonnat, New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes, Oncotarget, vol.9, issue.48, pp.28866-28876, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01929708

E. Tiacci, V. Trifonov, and G. Schiavoni, BRAF mutations in hairycell leukemia, N Engl J Med, vol.364, issue.24, pp.2305-2315, 2011.

E. Matutes, A. Martínez-trillos, and E. Campo, Hairy cell leukaemia-variant: disease features and treatment, Best Pract Res Clin Haematol, vol.28, issue.4, pp.253-263, 2015.

F. Bertoni, D. Rossi, and E. Zucca, Recent advances in understanding the biology of marginal zone lymphoma, vol.7, p.406, 2018.

S. Perrone, D. 'elia, G. M. Annechini, and G. , Splenic marginal zone lymphoma: prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era, Leuk Res, vol.44, pp.53-60, 2016.

G. Kanellis, M. Mollejo, and S. Montes-moreno, Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases

, reveals characteristic clinico-pathological features, Haematologica, vol.95, issue.7, pp.1122-1129, 2010.

A. Travesre-glehen, L. Baseggio, G. Salles, B. Coiffier, P. Felman et al., Splenic diffuse red pulp small B cell lymphoma: toward the emergence of a new lymphoma entity, Discov Med, vol.13, pp.253-265, 2012.

T. Vig, T. A. Kodiatte, M. T. Manipadam, and F. N. Aboobacker, A rare case of splenic diffuse red pulp small B-cell lymphoma (SDRPL): a review of the literature on primary splenic lymphoma with hairy cells, Blood Res, vol.53, issue.1, p.71, 2018.

L. Jallades, L. Baseggio, and P. Sujobert, Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma, Haematologica, vol.102, issue.10, pp.1758-1766, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01583112

S. Curiel-olmo, R. Mondéjar, and C. Almaraz, Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations, Blood, vol.129, issue.8, pp.1042-1045, 2017.

A. Traverse-glehen, F. Berger, and . Pathologie-splénique, Cas no 2. Lymphome B de la zone marginale splénique, Ann Pathol, vol.30, issue.3, pp.206-210, 2010.

X. Troussard and E. Cornet, Hairy cell leukemia 2018: update on diagnosis, risk-stratification, and treatment, Am J Hematol, vol.92, issue.12, pp.1382-1390, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02194321

R. J. Kreitman, C. Dearden, and P. L. Zinzani, Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia, Leukemia, vol.32, issue.8, pp.1768-1777, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02194148

J. J. Buggy and E. L. Bruton, Tyrosine kinase (BTK) and its role in B-cell malignancy, Int Rev Immunol, vol.31, issue.2, pp.119-132, 2012.

R. W. Hendriks, S. Yuvaraj, and L. P. Kil, Targeting Bruton's tyrosine kinase in B cell malignancies, Nat Rev Cancer, vol.14, issue.4, pp.219-232, 2014.

M. Sivina, R. J. Kreitman, E. Arons, F. Ravandi, and J. A. Burger, The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach, Br J Haematol, vol.166, issue.2, pp.177-188, 2014.

J. Jones, L. Andritsos, and R. J. Kreitman, Efficacy and safety of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study, Blood, vol.128, issue.22, pp.1215-1215, 2016.